← Back to list
Clesrovimab-cfor (Enflonsia) (CPB 1088)
Effective date
Not stated in the notice
Identified
Sep 29, 2026
Summary
Aetna Clinical Policy Bulletin 1088, Clesrovimab-cfor (Enflonsia), addresses this RSV antibody for commercial medical plans. It states Aetna considers the CDC ACIP recommendations for a single intramuscular injection medically necessary to prevent RSV lower respiratory tract disease when the listed infant criteria are met. The source text does not state an effective date or describe what changed.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
Get Aetna alertsPolicy Monitoring is free. No card required.
What to do
Action · 2 steps
01Billing team: for commercial plans, before billing CPT 90382, confirm the infant meets one of the bulletin's criteria, such as being under 8 months old in the first RSV season and not having received a clesrovimab-cfor, nirsevimab-alip or palivizumab dose.
02Check the maternal RSV vaccine status the bulletin lists.
Codes mentioned
90382B20B97.4Z29.11Z95.1Z99.81
Original notice
Clesrovimab-cfor (Enflonsia) (CPB 1088)
aetna.com · Always check the source before changing claims.
Related changes
See all Aetna changes →Clesrovimab-cfor (Enflonsia) (CPB 1088, reviewed 2026-10-09)MediumEffective Oct 9, 2025 · Medical PolicyNirsevimab-alip (Beyfortus) (CPB 1038, reviewed 2026-10-09)MediumEffective Sep 12, 2023 · Medical PolicyNirsevimab-alip (Beyfortus) (CPB 1038, reviewed 2025-10-09)MediumNo effective date · Medical PolicyClesrovimab-cfor (Enflonsia) (CPB 1088, reviewed 09-2025-10)HighNo effective date · Medical PolicyBrowse every Aetna change in the policy list